Overview

A Study of MLN0264 in Patients With Pancreatic Cancer

Status:
Terminated
Trial end date:
2016-01-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy, safety and tolerability of MLN0264 in patients with advanced or metastatic guanylyl cyclase C (GCC)-positive adenocarcinoma of the pancreas.
Phase:
Phase 2
Details
Lead Sponsor:
Millennium Pharmaceuticals, Inc.